DCM
TEVA icon

Discovery Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Discovery Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,958,200
Closed -$194M – 125
2015
Q4 		$194M Buy
+2,958,200
New +$183M 2.3% 10

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Discovery Capital Management's TEVA Position: Q1 2016 in Review

Discovery Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 2,958,200 shares — an estimated $194M sold.

Discovery Capital Management first reported a position in TEVA in Q4 2015 and held it in 1 quarter. The position peaked at $194M in Q4 2015. 837 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

  • Discovery Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Discovery Capital Management sold 2,958,200 Teva Pharmaceuticals shares in Q1 2016, an estimated $194M.
  • Discovery Capital Management first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Discovery Capital Management's Teva Pharmaceuticals position peaked at $194M in Q4 2015.
  • 837 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on Discovery Capital Management's 13F filing for Q1 2016, filed 16 May 2016.